Speakers
Alicia Heapy, PhD
Associate Professor
Yale School of Medicine
Department of Psychiatry
Co-Director VA Pain/Opioid Consortium of Research
VA Connecticut Healthcare System
Diana Higgins, PhD
Clinical Psychologist
MBHI-Neurology
VA Connecticut Healthcare System
Keywords
Chronic Pain; Cognitive Behavioral Therapy; Veterans Administration; Superiority Trial; Barriers
Key Points
- Cognitive behavioral therapy for chronic pain (CBT-CP) is an underutilized first-line treatment that improves pain and functional outcomes. Barriers to use remain, from patient barriers like the need to travel and mobility issues to system barriers like clinician scarcity and the prevalence of pain.
- COPES ExTRA was a pragmatic, hybrid type 1 superiority trial that sought to assess the effectiveness of self-directed CBT-CP relative to clinician-delivered CBT-CP among adults with chronic musculoskeletal pain. The research team sought to evaluate the strengths and weaknesses of each approach and inform future clinical use of CBT-CP in the Veterans Health Administration.
- They found that, while both arms saw clinically significant improvements, patients who received self-directed CBT-CP showed superior improvements on pain interference, pain intensity, sleep, and depressive symptoms durable to 12 months. Convenient, scalable self-directed CBT-CP may be an effective alternative to clinician-directed therapy.
- Self-directed participants waited fewer days to start treatment and attended more treatment sessions. Factors that contributed to the success of self-directed CBT-CP included fidelity or consistency; the therapeutic elements of daily diary/feedback; walking; and faster time to treatment.
Discussion Themes
Pragmatic methods yielded a sample representative of patients receiving care in the Veterans Health Administration.
Adapting the model outside integrated health systems faces major billing and administrative hurdles, particularly regarding CPT coding and insurance reimbursement for asynchronous coaching.
Standardized effect sizes reached 0.43–0.44 for the primary outcome and 0.3–0.4 across secondary measures, comparing favorably to or exceeding effect sizes typically achieved in non-pharmacological chronic pain trials.
Recruiting and onboarding clinical sites required extensive effort; some clinicians were wary of automated electronic health record alerts generating overwhelming surges in patient referrals or impacting workload metrics.